Staphylococcus Aureus Bacteraemia (SAB)-Support-Study (SABOT)

SAB-Support-Study: Can Checklist-based Phone Calls Improve the Quality of Staphylococcus Aureus Bacteraemia (SAB) Management

The main objective of this study is to investigate whether checklist-based close telephone consultation and process surveillance for S. aureus bacteraemia (SAB) can improve adherence to our in-house SAB-guidelines (prospective quality- improvement group).

In addition, the effects of telephone consultation on the clinical outcome of patients will be examined.

Study Overview

• Status: Completed
• Conditions: Staphylococcus Aureus Bacteremia
• Intervention / Treatment: Other: Checklist-based phone calls

• Study Type: Interventional
• Enrollment (Actual): 124
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Germany
  • Greifswald, Germany
    • Greifswald University Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• ≥ 18 years
• Inpatient treatment at the University Medicine Greifswald university hospital
• First diagnosis of SAB in hospital

Exclusion Criteria:

• SAB already known before admission
• Palliative management within 48 hrs after SAB diagnosis
• Death within 48 hrs after SAB diagnosis
• Hospital discharge within 48hrs after SAB diagnosis

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Retrospective control group (n= 62); Analysis of patients with the diagnosis of S. aureus-bacteraemia between 01.10.2022-01.10.2023
Other: Prospective quality-improvement group (n= 62); Analysis of patients with the diagnosis of S. aureus-bacteraemia between 22.01.2024-22.01.2025	Other: Checklist-based phone calls; The treating doctor will be called on day 1 and 12 after SAB diagnosis to point out the standard of care (as per our evidence-based in-hospital standard operating procedure (SOP)) for SAB. On day 2 and 6 after SAB diagnosis, there will be additional phone calls if clinical management does not follow hospital guidelines. The study team will also leave comments in the medical charts of the respective patients if the management does not follow hospital guidelines.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
SOP adherence, calculated as a sum score per patient with the following 8 parameters:	Drawing of follow-up blood cultures 2-3 days after start of adequate antibiotic therapy; Early source control (removal of infected material or drainage of an abscess ≤ 72 hrs); Adequate search for SAB focus and metastatic manifestations; TEE in patients with clinical indications (within 4 days of SAB diagnosis); Early start of specific therapy after receipt of results via phone call (≤12 hrs); Adequate dosage of antibiotic; Sufficient duration of therapy (at least 14 d for uncomplicated bacteremia and 28 d for complicated bacteremia); Combination therapy with Rifampicin or Fosfomycin, when indicated	Hospital admission until hospital discharge (no later than day 90 after diagnosis)

Secondary Outcome Measures

Outcome Measure	Time Frame
Time to specific antimicrobial treatment according to guidelines concerning agent and duration	Hospital admission until hospital discharge (no later than day 90 after diagnosis)
Time to negativity of follow up blood cultures	Day of SAB diagnosis until hospital discharge (no later than day 90 after diagnosis)
Time till TEE is performed (when indicated)	Hospital admission until hospital discharge (no later than day 90 after diagnosis)
Length of hospital stay after SAB diagnosis	Day of SAB diagnosis until hospital discharge (no later than day 90 after diagnosis)
In-hospital mortality (all patients)	Hospital admission until hospital discharge (no later than day 90 after diagnosis)
In-hospital mortality (because of SAB complications)	Hospital admission until hospital discharge (no later than day 90 after diagnosis)
Hospital readmission until day 30 after SAB diagnosis (all patients)	Day of SAB diagnosis until day 30 after diagnosis
Hospital readmission until day 30 after SAB diagnosis (because of SAB complications)	Day of SAB diagnosis until day 30 after diagnosis
Hospital readmission until day 90 after SAB diagnosis (all patients)	Day of SAB diagnosis until day 90 after diagnosis
Hospital readmission until day 90 after SAB diagnosis (because of SAB complications)	Day of SAB diagnosis until day 90 after diagnosis
90-day all-cause mortality	Day of SAB diagnosis until day 90 after diagnosis
90-day mortality because of SAB complications	Day of SAB diagnosis until day 90 after diagnosis
Relapse of bacteremia until day 90 after diagnosis	Day of SAB diagnosis until day 90 after diagnosis
Quality of discharge summary (documentation and treatment plan), calculated as a sum score	Hospital admission until hospital discharge (no later than day 90 after diagnosis)
Infectious diseases consultation, when indicated (yes/no)	Hospital admission until hospital discharge (no later than day 90 after diagnosis)

Collaborators and Investigators

• Sponsor: University Medicine Greifswald

Study record dates

Study Major Dates

• Study Start (Actual): January 22, 2024
• Primary Completion (Actual): November 19, 2024
• Study Completion (Actual): January 18, 2025

Study Registration Dates

• First Submitted: January 19, 2024
• First Submitted That Met QC Criteria: January 31, 2024
• First Posted (Actual): February 8, 2024

Study Record Updates

• Last Update Posted (Actual): November 21, 2025
• Last Update Submitted That Met QC Criteria: November 17, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Keywords: Bacteremia; Staphylococcus aureus
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Sepsis; Systemic Inflammatory Response Syndrome; Inflammation; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Pathological Conditions, Signs and Symptoms; Staphylococcal Infections; Bacteremia
• Other Study ID Numbers: BB 140/23

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No